Trial Profile
An Open Label Dose Adjusted Phase II Trial of the Oral Farnesyltransferase Inhibitor (FTI) Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lonafarnib (Primary)
- Indications Progeria
- Focus Therapeutic Use
- 23 May 2017 Status changed from active, no longer recruiting to completed.
- 23 May 2017 Status changed from active, no longer recruiting to completed.
- 16 Jun 2014 New trial record